FDA approves Vera Therapeutics kidney disease treatment
The FDA has approved Vera Therapeutics' drug Trutakna to treat primary IgA nephropathy, sparking a new market competition for kidney disease treatments.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The US FDA has granted approval for Trutakna, a dual-target drug developed by Vera Therapeutics. The medication is approved to reduce proteinuria in patients suffering from primary IgA nephropathy.
Coverage from Reuters, STAT, and Fierce Pharma emphasizes that this approval positions Vera Therapeutics for a market battle against competitors including Novartis and Otsuka. The Business Journals highlighted a patient's experience of returning to a normal life following the drug's use.
Future developments center on the market competition between Vera Therapeutics and established pharmaceutical firms in the IgAN space.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Who reported it (11)
- Vera Therapeutics wins FDA nod for closely watched kidney disease drug BioPharma Dive · 45d ago
- Vera Therapeutics Receives FDA Accelerated Approval for GlobeNewswire · 45d ago
- 🔎 Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA WSJ · 45d ago
- US FDA Approves Trutakna For Proteinuria In Primary Immunoglobulin A Nephropathy TradingView · 45d ago
- VERA Stock Set To Snap 3-Session Slide Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug Stocktwits · 45d ago
- What Trutakna's Approval Means for Specialty Launches Pharmaceutical Commerce · 45d ago
- 'I got back to living my normal life': How Vera Therapeutics' drug renewed a kidney patient ahead of FDA test The Business Journals · 45d ago
- Trutakna Approved to Reduce Proteinuria in Primary IgA Nephropathy Medical Professionals Reference · 45d ago
- FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka Fierce Pharma · 45d ago
- US FDA approves Vera's kidney disease drug Reuters · 45d ago
- FDA approves Vera Therapeutics kidney disease treatment STAT · 45d ago broke it first
Quick answers
What is Trutakna used for?
It is used to reduce proteinuria in patients with primary IgA nephropathy.
Who are the primary competitors in this market?
According to Fierce Pharma, Novartis and Otsuka are the key competitors.
What is unique about the drug's design?
Coverage describes Trutakna as a dual-target treatment.
People, places & organizations
Topics
Related trends
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.